Aims The aim of this study was to identify a subset of patients at high risk of bleeding or
myocardial infarction from a percutaneous coronary intervention and to investigate whether …

Aims Given controversy over anticoagulation regimens for percutaneous coronary
intervention (PCI), we performed an updated meta-analysis of randomized controlled trials …

Randomized controlled trials have shown improved short-term bleeding outcomes for
bivalirudin compared to unfractionated heparin (UFH) in patients undergoing percutaneous …

Background Bivalirudin, as compared with unfractionated heparin (UFH), has been shown to
reduce bleeding complications and supply a better safety profile among low/medium …

Bivalirudin, a direct thrombin inhibitor, is as effective as unfractionated heparin (UFH), with
decreased bleeding in patients with acute coronary syndromes who undergo percutaneous …

Objectives The primary objective of this study is the compare the association between
bleeding and the use unfractionated heparin (UFH) versus bivalirudin during percutaneous …

Background Bivalirudin reduces bleeding events and is associated with a lower mortality
than the combination of unfractionated heparin (UFH) and glycoprotein IIb/IIIa inhibitor …

Background—Data from randomized trials has demonstrated the superiority of bivalirudin to
glycoprotein IIb/IIIa inhibitors plus heparin in patients undergoing primary percutaneous …

Purpose The aim of this study was to explore the safety and efficacy of bivalirudin in elderly
patients undergoing percutaneous coronary intervention (PCI). Methods An electronic …

Objectives This study was undertaken to evaluate the safety of bivalirudin (BIV) use during
percutaneous coronary intervention (PCI), following thrombolytic therapy in patients with ST …